Gapping up
In reaction to strong earnings/guidance:
- JCP +20.2%, JD +13.3%, CRC +12.7%, RUBI +10.8%, COLL +9.3%, CVNA +8.8%, ENDP +8.3%, TWNK +8.2%, TPC +7.2%, MNST +6.9%, RGNX +6.1%, SOI +5.9%, ECA +5.8%, BILI +5.7%, FGEN +5.7%, BUD +5.6%, HGV +5%, KW +5%, JCAP +4.8%, NRG +4.8%, FTAI +4.6%, WTI +4.2%, CARS +3.6%, STAY +3.3%, NLSN +3.2%, FG +3.1%, ANSS +3.1%, GKOS +3%, ERI +2.9%, FOLD +2.7%, IRDM +2.6%, DAR +2.5%, UHS +2.5%, XLRN +2.4%, DAVA +2.4%, APA +1.4%, CWEN +1.4%, TTI +1.4%, FRO +1.3%, VET +1.2%, ATSG +1%
Other news:
- TTOO +24.5% (granted Breakthrough Device designation for the T2Resistance Panel by FDA)
- HZNP +23.1% (announces top-line results from Phase 3 confirmatory trial evaluating teprotumumab met primary endpoint)
- SRRA +15.4% (announces late-breaking oral and poster presentations for SRA737 and SRA141 preclinical data at AACR 2019)
- WBC +8.1% (WABCO Holdings confirms it has been approached by ZF Friedrichshafen AG and has engaged in preliminary discussions concerning a potential transaction)
- GH +7.1% (announces positive results from NILE study)
- TBIO +6.4% (provides update on cystic fibrosis and ornithine transcarbamylase deficiency programs; FDA to require additional preclinical toxicology data for MRT5201)
- ECA +5.8% (receives regulatory approvals for its planned $1.25 bln share buyback)
- IMGN +5.4% (modestly rebounding)
- KPTI +2.7% (Point72 Asset Management increases passive stake)
- BMY +1.9% (Bristol-Myers Squibb 8% shareholder Wellington Management says does not support proposed acquisition of Celgene)
Analyst comments:
- HAIN +6.4% (upgraded to Overweight from Neutral at JP Morgan)
- ENPH +2.8% (target raised to $12 at H.C. Wainwright)
- GMED +1.7% (upgraded to Buy from Neutral at UBS)
- VSTO +0.9% (initiated with a Buy at B. Riley
Gapping down
In reaction to disappointing earnings/guidance:
- BOX -23.2%, FIT -15.9%, TDOC -15.8%, WIFI -14.6%, HPQ -14.5%, CROX -10.6%, ORBC -9.9%, BKNG -9.8%, PRAH -6.9%, HX -6.9%, SQ -6.1%, PK -5.9%, LB -5.7%, PDCE -5.7%, ITRI -5.6%, AYX -5.5%, ESTC -5.1%, WING -4.1%, SPAR -4.1%, PRGO -3.9%, PRTY -3.5% (also - CFO Dan Sullivan to leave the company effective March 22 to pursue other opportunities) LADR -3.3%, SEAS -3.2%, ABB -3%, AMED -2.8%, SJI -2.4%, SEMG -2.3%, AMRX -2.3%, SQM -2.2%, BTI -2.1%, ICPT -1.9%, SRPT -1.8%, FSK -1.8%, BGNE -1.8%, GPOR -1.4%, TD -1.3%, AKRX -1.3%
Other news:
- NVAX -66% (topline results from Phase 3 Prepare Trial of ResVax - did not meet primary objective)
- SYNH -27.9% (delayed its previously announced earnings release/call to allow additional time to complete its Form 10-K)
- AAOI -9.8% (announces proposed private offering of $70 mln aggregate principal amount of Convertible Senior Notes due 2024)
- CELG -7.8% (Bristol-Myers Squibb 8% shareholder Wellington Management says does not support proposed acquisition of Celgene)
- UNIT -6.6% (postpones Q4 release to assess the impact of the bankruptcy petition by Windstream Holdings)
- SKY -6.3% (prices secondary offering of 10,750,202 shares of its common stock by certain of its shareholders at $20.46 per share)
- KOS -5.6% (attributed to block trade pricing)
- ALDR -2.6% (prices offering of 11,304,348 shares of common stock at $11.50 per share)
- NOVT -1.6% (after closing 8% higher on the day; files for debt securities and common share shelf offering)
- EXPE -1.5% (following BKNG results)
- TRIP -1% (following BKNG results)
Analyst comments:
- CERN -3% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- BIG -2.1% (downgraded to Hold from Buy at Deutsche Bank)
- AMT -1.8% (downgraded to Perform from Outperform at Oppenheimer)
- VCEL -1.4% (downgraded to Hold from Buy at Needham)
- TREE -1.3% (downgraded to Neutral from Buy at UBS)
- TOL -1.2% (downgraded to In-line from Outperform at Evercore ISI)